Drug Trial Radar · NCT04882878
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
Aug 20, 2021
Primary completion
Apr 30, 2024
Study completion Dec 26, 2024
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus
Interventions
PlaceboOther
Placebo will be administered intravenously.
NipocalimabDrug
Nipocalimab dose 1 and dose 2 will be administered intravenously.
Standard-of-care treatmentDrug
Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 24Time frame: Week 24
Locations
86 sites in 12 countries. Site status is shown where the registry gives one.
Valerius Medical Group & Research Center
Los Alamitos, California
Desert Medical Advances
Rancho Mirage, California
Wolverine Clinical Trials
Santa Ana, California
Millennium Clinical Trials LLC
Westlake Village, California
Bay Area Arthritis and Osteoporosis
Brandon, Florida
GNP Research
Cooper City, Florida
South Coast Research Center
Miami, Florida
Advanced Clinical Research of Orlando
Ocoee, Florida
Omega Research Consultants
Orlando, Florida
Millennium Research
Ormond Beach, Florida
North Georgia Rheumatology, PC
Lawrenceville, Georgia
Atlanta Research Center for Rheumatology
Marietta, Georgia
West County Rheumatology
St Louis, Missouri
DJL Clinical Research, PLLC
Charlotte, North Carolina
Paramount Medical Research & Consulting
Middleburg Heights, Ohio
Dr. Ramesh Gupta
Memphis, Tennessee
Arthritis and Rheumatology Research Institute
Allen, Texas
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Southwest Rheumatology Research LLC
Mesquite, Texas
Epic Medical Research
Red Oak, Texas
Rheumatology and Pulmonary Clinic
Beckley, West Virginia
Centro Médico Reumatológico (OMI)
Buenos Aires, Argentina
Centro Privado de Medicina Familiar
Buenos Aires, Argentina
ARCIS Salud SRL Aprillus asistencia e investigacion
CABA, Argentina
Clinica Adventista Belgrano
Ciudad de Buenos Aires, Argentina
Hospital Italiano La Plata
La Plata, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Argentina
Instituto de Reumatologia - Ir Medical Center S.A.
Mendoza, Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina
Multiprofile Hospital for Active Treatment Plovdiv
Plovdiv, Bulgaria
Diagnostic-Consultative Center (DCC) Aleksandrovska
Sofia, Bulgaria
UMHAT St. Ivan Rilski
Sofia, Bulgaria
Clinica de la Costa SAS
Barranquilla, Colombia
Centro de Investigacion Medico Asistencial SAS - CIMEDICAL SAS
Barranquilla, Colombia
Centro de Investigación en Reumatología y especialidades médicas S.A.S. - CIREEM S.A.S.
Bogotá, Colombia
Servimed S A S
Bucaramanga, Colombia
IPS Preventive Care SAS
Chía, Colombia
Praxis Dr. med. Beate Schwarz - Germany
Langenau, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
Budapest, Hungary
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.